Home › Appendiceal Cancer › NCT07587268

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.
* Availability of archived tumor tissue suitable for molecular profiling.
* Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.
* Availability of relevant clinicopathologic data.
* Availability of survival or follow-up information when applicable.
* Age 18 years or older at diagnosis or tissue collection.

Exclusion Criteria:

* Insufficient tissue quantity or quality for molecular profiling.
* Inadequate DNA or RNA quality for sequencing or molecular assay preparation.
* Missing essential clinicopathologic information required for analysis.
* Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.
* Patients who do not meet institutional review board or consent requirements, if applicable.

About the study

This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.

What is being tested

• DNA Methylation Profiling (diagnostic test)
• m6A Epitranscriptomic Profiling (diagnostic test)

Sponsor: City of Hope Medical Center · Participants: 400 · Started: May 1, 2026

Contact the study team

• Ajay Goel · Phone: 6262184673

Official record on ClinicalTrials.gov — NCT07587268

Locations in the U.S.

Conditions

• Appendiceal Cancer
• Mucinous Adenocarcinoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.